The Top 5 Biosimilar Articles for the Week of November 9

Video

Here are the top 5 biosimilar articles for the week of November 9, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 9, 2020.

Number 5: Investigators at the American College of Rheumatology (ACR) Convergence 2020 meeting presented evidence of what they say are successful, first-time tests of a multibiomarker disease activity (MBDA) score in patients with rheumatoid arthritis (RA).

Number 4: Medicines for Europe, a generic and biosimilar trade association, contends in a white paper that legal and regulatory loopholes increasingly keep competing drugs off the market

Number 3: Separate studies including one on application methods for Celltrion’s adalimumab biosimilar (CT-P17) were reported at the ACR Convergence 2020 meeting.

Number 2: Alberta, Canada’s deadline for switching patients to biosimilars is months away, but the province has already seen some success with the new program.

Number 1: Biosimilar developments reported at the ACR Convergence 2020 virtual meeting included data from safety and efficacy trials for Pfizer and Celltrion versions of adalimumab.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of September 11, 2023.
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of August 28, 2023.
Here are the top 5 biosimilar articles for the week of August 28, 2023.
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of August 21, 2023.
Here are the top 5 biosimilar articles for the week of August 14, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.